For the quarter ended June 2025, Hologic (HOLX Quick QuoteHOLX - Free Report) reported revenue of $1.02 billion, up 1.2% over the same period last year. EPS came in at $1.08, compared to $1.06 in the year-ago quarter.

The reported revenue represents a surprise of +1.68% over the Zacks Consensus Estimate of $1.01 billion. With the consensus EPS estimate being $1.05, the EPS surprise was +2.86%.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Hologic performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenues- Breast health- Breast imaging: $264.7 million versus $277.39 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -14.4% change.
• Revenues- Skeletal health: $31.3 million versus $25.34 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a +64.7% change.
• Revenues- Diagnostics- Cytology and perinatal: $121.4 million versus $117.36 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -0.7% change.
• Revenues- Diagnostics- Molecular diagnostics: $320.5 million compared to the $316.12 million average estimate based on three analysts. The reported number represents a change of +3.2% year over year.
• Revenues- Diagnostics- Blood screening: $7 million versus $5.65 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -11.4% change.
• Revenues- Total Diagnostics: $448.9 million versus the three-analyst average estimate of $437.46 million. The reported number represents a year-over-year change of +1.8%.
• Revenues- Breast health- Interventional breast solutions: $100.5 million versus the three-analyst average estimate of $85.76 million. The reported number represents a year-over-year change of +32.6%.
• Revenues- Total Breast health: $365.2 million compared to the $363.15 million average estimate based on three analysts. The reported number represents a change of -5.1% year over year.
• Revenues- GYN surgical: $178.4 million versus the three-analyst average estimate of $179.82 million. The reported number represents a year-over-year change of +7.1%.
• Revenues- Product: $810.4 million versus $801.5 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -0.1% change.
• Revenues- Service and other: $213.4 million versus the two-analyst average estimate of $202.73 million. The reported number represents a year-over-year change of +6.6%.

View all Key Company Metrics for Hologic here>>>

Shares of Hologic have returned +1.1% over the past month versus the Zacks S&P 500 composite's +3.4% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.